Two new drugs for melanoma after first treatment fails
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests two new drugs (cadonilimab and anlotinib) for people with melanoma that has spread or grown after their first treatment. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have a confirmed diagnosis of melanoma (a type of skin cancer).
- Your first treatment for melanoma must have failed (stopped working or caused severe side effects).
- You must be able to take care of yourself and be up and about (ECOG score 0 or 1).
- You must have at least one tumor that can be measured on a scan.
- If you have brain or liver metastases, they must be stable and not causing symptoms (brain metastases must have been stable for 3 months and not require steroids).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of three drugs (relatlimab, ipilimumab, and nivolumab) as a first treatment for advanced melanoma that cannot be removed by surgery. All participants will receive the drug combination, and the study will look at safety and how well it works.
This trial is testing a combination of two immunotherapy drugs (anti-LAG-3 and anti-PD-1 antibodies) to see if they work better than standard treatment for people with advanced melanoma that hasn't been treated before. It may be an option if you have not yet received any systemic therapy for your melanoma.
This trial tests a combination of three drugs (interferon, an immunotherapy drug called toripalimab, and an anti-cancer drug called anlotinib) in people with advanced melanoma that cannot be removed with surgery. The goal is to see if this combination can help shrink or control the cancer.
This trial tests a combination of three immunotherapy drugs (relatlimab, nivolumab, and ipilimumab) for people with melanoma that has spread to the brain. It aims to see if this treatment can shrink brain tumors and improve outcomes.
This trial tests a combination of two drugs (cadonilimab and interferon) given before surgery to treat advanced melanoma that has spread to nearby lymph nodes or one distant site. The goal is to shrink tumors and improve chances of successful surgery and long-term survival.
This study tests a new drug called Cardonilmab for people with advanced melanoma or kidney cancer who have already tried other treatments. The goal is to see if the drug is safe and helps shrink or control the cancer.
Hear when a new Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.